Survival rates of patients with metastatic malignant melanoma. 2014

A Sandru, and S Voinea, and E Panaitescu, and A Blidaru
Department of Surgical Oncology, "Carol Davila" University of Medicine and Pharmacy; "Alexandru Trestioreanu" Oncologic Institute, Bucharest.

BACKGROUND Malignant melanoma (MM) is the cutaneous neoplasia with the greatest mortality rates and one of the malignancies with the highest potential of dissemination. The prognosis of patients with metastatic MM is grim, with a 5-years survival rate between 5-19%, and is dictated by the location and the number of metastases. OBJECTIVE We aimed to estimate the survival of patients with metastatic MM from our study and find out if the metastasis' location influences survival. RESULTS Between 2008 and 2013, 155 patients with cutaneous MM were diagnosed in our clinic. All the patients were staged according to 2009 AJCC staging system. The median follow-up period was of 24 months. Survival was calculated by using the Kaplan-Meier method with a confidence level of 95%. 40.5% of the patients developed metastases in different organs, especially the brain. 80.6% of those with metastases died during the study. The median overall survival, estimated for the entire group of patients who developed metastases, was of 5.3 months. CONCLUSIONS The influence of metastases distribution on the overall survival was examined and it was noticed that there were statistically significant differences between the risks of death of various groups of patients, depending on metastasis topography. Thus, the death probability of a patient with brain metastases is twice that of a patient with digestive metastasis, about 7 times higher than that of a patient with lung metastasis (p=0.0004) and 12 times higher than the death risk of a patient with extra-regional lymph nodes or subcutaneous metastasis (p=0.0000).

UI MeSH Term Description Entries
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000096142 Melanoma, Cutaneous Malignant A primary melanoma that originates from atypical skin MELANOCYTES, especially from acquired and congenital MELANOCYTIC NEVI, and DYSPLASTIC NEVI. FAMMM Syndrome,Familial Atypical Mole-Malignant Melanoma Syndrome,Dysplastic Nevus Syndrome, Hereditary,Melanoma, Familial,Cutaneous Malignant Melanoma,Cutaneous Malignant Melanomas,FAMMM Syndromes,Familial Atypical Mole Malignant Melanoma Syndrome,Familial Melanoma,Familial Melanomas,Malignant Melanoma, Cutaneous,Malignant Melanomas, Cutaneous,Melanomas, Cutaneous Malignant,Melanomas, Familial,Syndrome, FAMMM,Syndromes, FAMMM
D012878 Skin Neoplasms Tumors or cancer of the SKIN. Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival
D053208 Kaplan-Meier Estimate A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995) Kaplan-Meier Survival Curve,Kaplan-Meier Analysis,Kaplan-Meier Survival Curves,Kaplan-Meier Test,Product-Limit Method,Analysis, Kaplan-Meier,Curve, Kaplan-Meier Survival,Curves, Kaplan-Meier Survival,Estimate, Kaplan-Meier,Kaplan Meier Analysis,Kaplan Meier Survival Curve,Kaplan Meier Survival Curves,Kaplan Meier Test,Method, Product-Limit,Methods, Product-Limit,Product Limit Method,Product-Limit Methods,Survival Curve, Kaplan-Meier,Survival Curves, Kaplan-Meier,Test, Kaplan-Meier

Related Publications

A Sandru, and S Voinea, and E Panaitescu, and A Blidaru
January 1977, Annales chirurgiae et gynaecologiae,
A Sandru, and S Voinea, and E Panaitescu, and A Blidaru
March 1986, Surgery, gynecology & obstetrics,
A Sandru, and S Voinea, and E Panaitescu, and A Blidaru
October 1979, American journal of ophthalmology,
A Sandru, and S Voinea, and E Panaitescu, and A Blidaru
June 1979, American journal of ophthalmology,
A Sandru, and S Voinea, and E Panaitescu, and A Blidaru
July 1991, Clinical and experimental dermatology,
A Sandru, and S Voinea, and E Panaitescu, and A Blidaru
May 1972, Missouri medicine,
A Sandru, and S Voinea, and E Panaitescu, and A Blidaru
July 1994, The Canadian journal of urology,
A Sandru, and S Voinea, and E Panaitescu, and A Blidaru
May 2015, Current medical research and opinion,
A Sandru, and S Voinea, and E Panaitescu, and A Blidaru
August 1993, Annals of the New York Academy of Sciences,
A Sandru, and S Voinea, and E Panaitescu, and A Blidaru
April 1987, Journal of surgical oncology,
Copied contents to your clipboard!